ZTS

Healthcare

Zoetis

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2011–2025(15yr)

Revenue

Net Income

Free CF

Metric	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$4.2B	$4.3B	$4.6B	$4.8B	$4.8B	$4.9B	$5.3B	$5.8B	$6.3B	$6.7B	$7.8B	$8.1B	$8.5B	$9.3B	$9.5B	+2.3%
Gross Profit	$2.6B	$2.8B	$2.9B	$3.1B	$3.0B	$3.2B	$3.5B	$3.9B	$4.3B	$4.6B	$5.5B	$5.6B	$6.0B	$6.5B	$6.8B	+4.0%
Gross Margin	61.0%	64.0%	63.4%	64.1%	63.5%	65.9%	66.6%	67.2%	68.2%	69.2%	70.4%	69.6%	70.0%	70.6%	71.8%	+1.2pp
Net Income	$245.0M	$436.0M	$504.0M	$583.0M	$339.0M	$821.0M	$864.0M	$1.4B	$1.5B	$1.6B	$2.0B	$2.1B	$2.3B	$2.5B	$2.7B	+7.5%
Net Margin	5.8%	10.1%	11.1%	12.2%	7.1%	16.8%	16.3%	24.5%	24.0%	24.5%	26.2%	26.2%	27.4%	26.9%	28.2%	+1.4pp
Free Cash Flow	$362.0M	$328.0M	$497.0M	$446.0M	$440.0M	$497.0M	$1.1B	$1.5B	$1.3B	$1.7B	$1.7B	$1.3B	$1.6B	$2.3B	$2.3B	-0.7%
FCF Margin	8.6%	7.6%	10.9%	9.3%	9.2%	10.2%	21.1%	24.9%	21.3%	25.1%	22.3%	16.4%	19.0%	24.8%	24.1%	-0.7pp
EPS (Diluted)	$0.49	$0.87	$1.01	$1.16	$0.68	$1.65	$1.75	$2.93	$3.11	$3.42	$4.27	$4.49	$5.07	$5.47	$6.02	+10.1%

Total Debt$9.0B

Cash & Equiv.$1.6B

Net Debt$7.5B

3 min read

1. THE BIG PICTURE

Zoetis is a high-margin cash machine that has traded rapid growth for defensive stability. While it leads its peer group in every profitability metric—keeping nearly 30 cents of every dollar as net profit—it is currently the slowest-growing company among its competitors (XBRL). The central tension for the business is whether its "lifecycle innovation" can defend its massive market share against a rising tide of generic competitors.

2. WHERE THE RISKS HIT HARDEST

Zoetis’s reliance on "significant brand loyalty" (10-K Item 1) is being directly challenged by lower-priced alternatives. This vulnerability is most evident in products that have lost patent protection, such as Rimadyl and Draxxin, which saw sales collapses of 39% and 66%, respectively (Risks).

Furthermore, the "integrated portfolio" management touts as a strength (10-K Item 1) is remarkably top-heavy. With just five product lines—including Simparica and Apoquel—accounting for 42% of total revenue, any safety concern or manufacturing disruption in these core brands would have a disproportionate impact on Zoetis’s ability to service its $9.2 billion debt load (Risks).

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a business that is essentially "buying" its growth through efficiency and capital allocation rather than raw sales expansion. While revenue growth of 2.3% is the lowest in the peer group, Zoetis maintains a peer-leading 24.7% Free Cash Flow (FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders) margin and a 34.7% operating margin (XBRL).

In the most recent quarter, revenue grew 3%, a slight acceleration from the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter average. This was driven by an 8% jump in the International segment, which helped offset a flat performance in the U.S. (8-K). In the U.S., growth in parasitides was neutralized by a decline in monoclonal antibody pain products like Librela and Solensia (8-K). To compensate for this sluggish organic growth, Zoetis returns 3.0% of its market cap to investors via buybacks—the highest yield among its peers—effectively manufacturing earnings-per-share growth even when volume is soft (Peer Benchmarking).

4. IS IT WORTH IT AT THIS PRICE?

At 16.0x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, the market is pricing in ~3.5% long-term growth (CAPM). This represents a modest discount to the peer median of 18.7x, which is justified by Zoetis’s position as the slowest grower in the group (+2.3% vs. IDXX’s +10.4%).

The 3.5% implied growth rate is highly credible because Zoetis’s 3.0% buyback yield does most of the heavy lifting; Zoetis only needs to find 0.5% of organic growth to satisfy current market expectations. However, the valuation is sensitive to further deceleration. If long-term growth slows to 2.5%, the justified multiple would fall to 13.8x, representing roughly 14% downside (CAPM). The current price is essentially a bet that international livestock growth (+12% organic) can continue to mask the stagnation in the U.S. companion animal market.

5. WHAT WOULD CHANGE THIS VIEW?

Cautious if U.S. companion animal sales remain flat for consecutive quarters or if the decline in monoclonal antibody pain products (Librela/Solensia) accelerates, suggesting a loss of clinical confidence (8-K).
Constructive if the "Vetscan Imagyst" AI platform or other diagnostic products begin to contribute a larger share of revenue, diversifying Zoetis away from its concentrated five-product core (Business).

6. BOTTOM LINE

Structural Advantage: Zoetis maintains a dominant market position through its massive direct sales force and a high-margin portfolio protected by deep brand loyalty among veterinarians.

Bottom Line: The stock is a premier defensive play for investors who value elite cash generation and shareholder returns over aggressive top-line expansion.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

Competitive Pressure: The animal health industry is highly competitive, with rivals possessing greater financial and technical resources. Consolidation among competitors may improve their pricing power, while the entry of lower-priced generic alternatives to products that have lost patent protection—such as the 39% and 66% sales declines seen in Rimadyl chewable and Draxxin, respectively—directly threatens Zoetis’s revenue.
Concentration of Revenue: Zoetis’s financial performance is heavily dependent on its five top-selling product lines (Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, and the ceftiofur line), which contributed approximately 42% of total revenue in 2025. Any safety concerns, manufacturing disruptions, or loss of patent protection for these specific products would have a disproportionate impact on results.
Product Safety and Efficacy: Unanticipated safety or efficacy concerns, whether scientifically supported or merely perceived, can lead to product recalls, label changes, or negative publicity. Because Zoetis depends on positive perceptions from veterinarians and pet owners, such events can cause significant reputational harm and declining sales.
Global Economic and Political Conditions: Macroeconomic disruptions, including inflation, geopolitical instability (such as the conflict in Ukraine), and economic weakness in China, can reduce demand for products. These conditions may cause pet owners to defer veterinary visits or seek lower-priced alternatives, and can hinder Zoetis’s ability to collect payments from customers.
Indebtedness: Zoetis carries approximately $9.2 billion in total unsecured indebtedness. This high level of debt limits the ability to obtain additional financing, increases vulnerability to interest rate fluctuations, and imposes restrictive covenants that could lead to an event of default if not met.

2. Company-Specific Risks

Distribution Channel Shifts: As companion animal owners increasingly turn to internet-based retailers and "big-box" stores rather than traditional veterinary practices, Zoetis faces the risk of margin compression due to the increased purchasing power of these large-scale retailers.
Antibacterial Regulation: With approximately $713 million in 2025 revenue attributable to antibacterials for livestock, Zoetis is highly exposed to global regulatory trends and consumer preferences that favor antibiotic-free protein or restrict the use of specific antibacterials in food-producing animals.
Manufacturing Complexity: Zoetis operates a network of 21 manufacturing sites and over 90 third-party contract manufacturing organizations (CMOs). Sole-sourcing for many complex products means that minor deviations in manufacturing or logistical processes can lead to inventory shortages and unanticipated costs.
Pfizer Licensing Dependencies: Under the Patent and Know-How License Agreement, Zoetis relies on Pfizer to prosecute and maintain certain patents. If Pfizer fails to fulfill these obligations or terminates the agreement, Zoetis’s ability to commercialize products incorporating that intellectual property would be severely restricted.

3. Regulatory/Legal Risks

Data Privacy and AI Regulation: Zoetis is subject to a complex patchwork of global data privacy laws (e.g., GDPR, China’s PIPL, and various U.S. state laws). Failure to comply with these, or with emerging regulations regarding the use of AI, could result in substantial fines, regulatory investigations, and civil lawsuits.
Tax Disputes: Zoetis is currently defending its position regarding the one-time mandatory deemed repatriation tax following a September 2024 Revenue Agent Report issued by the IRS. An unfavorable outcome in this or other tax examinations could adversely affect Zoetis’s effective tax rate and cash flows.
Environmental and Chemical Regulation: Increasing focus on per- and polyfluoroalkyl substances (PFAS) by agencies like the European Chemicals Agency may lead to restrictions or phase-outs of products or packaging containing these substances, necessitating costly compliance measures.
Off-Label Use Liability: If Zoetis is deemed to have promoted products for off-label use, it could face significant fines, penalties, and mandatory modifications to promotional practices, which would damage its reputation and position within the industry.

4. Financial Impact Map

Generic Competition → Revenue → Historical declines of 39% and 66% in specific product lines following patent expiration.

Concentration of Top 5 Products → Revenue → 42% of total 2025 revenue derived from five product lines.

Antibacterial Restrictions → Revenue → $713 million in 2025 revenue attributable to livestock antibacterials.

Indebtedness → Liquidity/Cash Flow → $9.2 billion in total unsecured indebtedness as of December 31, 2025.

Goodwill/Intangible Asset Impairment → Consolidated Balance Sheets → $2.8 billion in goodwill and $1.0 billion in identifiable intangible assets as of December 31, 2025.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
8-K	Feb 2026	—
10-K	Feb 2026	Dec 2025
10-Q	Nov 2025	Sep 2025
14A	Apr 2025	—